Navigation Links
Patient safety advanced by revised heparin standards
Date:7/30/2009

Rockville, Md., July 30, 2009 Continuing to help ensure the identity, purity and quality of heparin, the U.S. Pharmacopeial (USP) Convention has revised written and physical standards for the widely used blood thinner. In February, USP released updated heparin standards at the request of the Food and Drug Administration (FDA) in response to the 2008 public health crisis in which more than 200 people died as a result of heparin adulterated for economic gain. A second phase of revisions is reflected in the newly posted standards. These developments and new information about heparin were discussed by scientists and regulators at the third International Heparin Workshop held at USP headquarters in Rockville, Maryland, July 27󈞈.

"While financially-motivated adulteration of medicines is a distressingly persistent problem," noted Roger L. Williams, M.D., USP's chief executive officer, "I'm pleased at the progress we've made in helping to ensure that such tragic events are minimized. Stronger methods for detecting a range of potential contaminants have been thoroughly assessed and incorporated into the new test methods, and the new physical reference standards are specific to these methods. Manufacturersand in consequence, physicians and their patientscan feel more confident of the purity and integrity of their heparin products."

The Workshop, co-sponsored by USP, the British National Institute of Biological Standards and Control (NIBSC), and the European Directorate for the Quality of Medicines (EDQM), reflected the global nature of both the problem of adulteration and the resources cooperating to combat it, with attendees from more than 17 countries.

The updated written standards are the Heparin Sodium Stage 2 Monograph and the Heparin Sodium Injection Stage 2 Monograph; new reference standards are Heparin Sodium for Assays, Oversulfated Chondroitin Sulfate, and Dermatan Sulfate. These and other related standards and informati
'/>"/>

Contact: Francine Pierson
fp@usp.org
301-816-8588
US Pharmacopeia
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Immune responses to flu vaccine are diminished in lupus patients
2. Tabyat Partners, LLC. Launches iluvmydoc.com™, to Better Connect Patients with Doctors
3. Michigan IT Companies Helping the University of Miami Center for Patient Safety Tackle a Leading Cause of Death Using an RTLS Solution to Monitor Staff Hand-Washing Compliance
4. Holy Family Memorial Health Network Bolsters Patient Care Quality and Safety in Achieving Stage 6 on HIMSS Analytics EMR Adoption Model(SM) Scale
5. NHLBI stops study of pulmonary hypertension treatment in sickle cell patients
6. Patients With Bipolar Disorder at Increased Risk for Wide Range of Health Problems, Thomson Reuters Study Finds
7. Photos: One Million Patients Choose Hologics NovaSure(R) System Over Hysterectomy
8. Save Swine Flu Drugs for Younger Patients, Study Urges
9. Surveyed Oncologists Expect to Prescribe Provenge to about Half of Their Prostate Cancer Patients if the Vaccine is Approved
10. Vivacare Expands Patient Education Service to Pediatricians
11. Fort Lauderdale Plastic Surgery Practice and Dr. Robert Rothfield Reaching Out to Patients with Expansive New Website
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... July 31, 2015 , ... Girl Scouts of Historic Georgia and Peach State ... Girl Scout "Be a Friend First" program. Representatives from Peach State Health Plan presented ... State Health Plan and our parent company, Centene Corporation, are dedicated to raising anti-bullying ...
(Date:7/31/2015)... IL (PRWEB) , ... July 31, 2015 , ... The ... Boston, when Major League Baseball and the Boston Red Sox honor Ice Bucket co-founders ... the challenge. MLB is donating $100,000 to further collaborative efforts among the ALS organizations ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... for the Northern District of Ohio, Western Division (Case No. 3:15-cv-00397) involving the ... 3:15-cv-00397), the women experienced spontaneous migration of their Implanon® implants, inability to locate ...
(Date:7/31/2015)... ... ... The alarm was ringing. Hugh Chatfield, survivor of a severe 1987 brain injury, almost slept ... equipment was set up to depict the newly poured concrete. With a clear view of ... speaks for itself. Chatfield is also a highly praised safety and drug education speaker/comedian. , ...
(Date:7/31/2015)... ... 2015 , ... Patients with higher levels of a key protein are at ... Communications and led by researchers from the Icahn School of Medicine at Mount Sinai. ... led to greater production of the related RNT1 protein, which caused kidney cells to ...
Breaking Medicine News(10 mins):Health News:Peach State Health Plan Presents $10,000 Check for “Be a Friend First” Anti-Bullying Program to Local Girl Scouts 2Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 2Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 3Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 4Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 2Health News:Can Implanon® (Etonogestrel Implant) Go Missing? Zoll, Kranz & Borgess, LLC Files Another Lawsuit on Behalf of Women with Lost or Migrated Implanon® Implants 3Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 2Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 3
... broke his silence for the first time. Since his parents broke ... problem of substance abuse. ,He revealed that he was ... He was being treated for a number of illnesses as a ... the name of the drug that he had been using. ...
... today issued the "Critical Path Opportunities for Generic Drugs" ... impede the development of generic versions of commonly used ... Critical Path Initiative, established in 2004 to discern what ... device along the critical path from discovery, or proof ...
... but a Dartmouth discovery that a cousin of niacin prolongs ... ,The research, reported in the May 4 issue ... yeast cells, much like calorie restriction does in animals. It ... ,Radical calorie reduction can extend life. Dieting or ...
... women who took an epilepsy drug during their pregnancy are ... In question is the drug valproate (already at the ... has damaged children). Valproate seems to double the chance that ... ,Around 140 British families claim that their children are ...
... research published in the journal Proceedings of the National ... produce// an antibiotic which inhibits the work of an ... from attack. ,Although such so-called gene-for-gene interactions ... examples of a single gene in a pathogen targeting ...
... an agency of the New York state government has lashed ... Hospital// as a shameful "chamber of filth, decay, indifference and ... Union, the agency has filed a suit in the federal ... where patients are subjected to overcrowded conditions, physical abuse and ...
Cached Medicine News:Health News:Cousins Recovering from His Substance Abuse Problem 2Health News:New Critical Path Report Highlights Research Needed to Foster Generic Drug Development 2Health News:Vitamin Extends Life in Yeast, Dartmouth Medical School Researchers Find 2Health News:Vitamin Extends Life in Yeast, Dartmouth Medical School Researchers Find 3Health News:Anti-Epileptic Drug Intake May Result In Children With Mental Retardation 2Health News:Scientists Discover Rare ‘gene-for-gene’ Interaction That Helps Bacteria Kill Their Ho 2Health News:Suit Filed Against Horrors of Psychiatric Ward in New York Hospital 2
(Date:7/31/2015)... , July 31, 2015  Boston Children,s ... benefiting from 3D printing of their anatomy before ... life-threatening cerebrovascular malformations (abnormalities in the brain,s blood ... Reporting online today in the Journal of ... of 3D printing and synthetic resins to create ...
(Date:7/31/2015)... , July 31, 2015 Egalet ... integrated specialty pharmaceutical company focused on developing, manufacturing ... closing of its previously announced underwritten public offering ... a public offering price of $11.25 per share. ... included 1,000,000 shares issued upon the exercise in ...
(Date:7/31/2015)... 31, 2015 According to a ... Product (Bioimpedance Analyzers (BIA), Dual-Energy X-ray Absorptiometry (DEXA), Skinfold ... Global Analysis & Forecast to 2019", published by MarketsandMarkets, ... $911.1 Million 2014 and is estimated to grow to ... 9.4% from 2014 to 2019. Browse ...
Breaking Medicine Technology:3D Printing Helps Doctors Rehearse Complex Brain Procedures 23D Printing Helps Doctors Rehearse Complex Brain Procedures 33D Printing Helps Doctors Rehearse Complex Brain Procedures 4Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Body Composition Analyzers Market Worth $1,425.7 Million by 2019 2Body Composition Analyzers Market Worth $1,425.7 Million by 2019 3Body Composition Analyzers Market Worth $1,425.7 Million by 2019 4
... BEIJING, Aug. 4, 2011 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, ... leading China-based advanced in-vitro diagnostic ("IVD") company, today announced ... the first fiscal quarter ended June 30, 2011 ("1Q ... 2011. The Company,s senior management will host ...
... N.J., Aug. 4, 2011 Omthera Pharmaceuticals, Inc., ... that Christian S. Schade will join the Company ... President and Chief Financial Officer, beginning in early ... experience as a public company financial executive in ...
Cached Medicine Technology:China Medical Technologies to Announce Results for the First Fiscal Quarter Ended June 30, 2011 on August 16, 2011 2Christian S. Schade to Join Omthera Pharmaceuticals as Executive Vice President and Chief Financial Officer 2Christian S. Schade to Join Omthera Pharmaceuticals as Executive Vice President and Chief Financial Officer 3
Freer elevator, double end, 7 1/4", S/B....
... The Surgifoam* absorbable gelatin sponge, U.S.P. ... gelatin absorbable sponge intended for hemostatic ... surface. The sponge is off-white and ... speed to hemostasis, highly favorable surgeon ...
... absorbable gelatin sponge, U.S.P. is a ... sponge intended for hemostatic use by ... sponge is off-white and porous in ... hemostasis, highly favorable surgeon preference ratings ...
16 mm diameter curved probes with suture eyes just back of blunt ends. Stainless steel. Round knurled handle with polished finish. Overall length: 5.7 inches....
Medicine Products: